Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection

Lavjay Butani, Joann Palmer, H. J. Baluarte, Martin S. Polinsky

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. Mycophenolate mofetil (MMF) has been shown to be superior to azathioprine in reducing the incidence of acute rejection in adult renal transplant recipients. Although MMF is also being widely used in pediatric transplant patients, data documenting its safety are limited. Methods. A retrospective review of the transplant records at St. Christopher's Hospital for Children was conducted to identify patients who had received MMF. Results. Twenty-four children were switched from azathioprine to MMF, 4.8±2.9 years after transplantation. After an additional 0.8±0.4 years, MMF had been discontinued in 13 patients (54%) because of adverse effects (AE). The only variable that predicted the development of AE was a lower calculated creatinine clearance at the time of initiation of MMF. Conclusions. In pediatric renal transplant recipients with impaired renal function, the use of MMF at the recommended dose is associated with an unacceptably high incidence of AE; in such patients, the MMF dose may require modification for the level of renal function.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalTransplantation
Volume68
Issue number1
StatePublished - Jul 15 1999
Externally publishedYes

Fingerprint

Mycophenolic Acid
Pediatrics
Kidney
Azathioprine
Transplants
Transplant Recipients
Incidence
Creatinine
Transplantation
Safety

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. / Butani, Lavjay; Palmer, Joann; Baluarte, H. J.; Polinsky, Martin S.

In: Transplantation, Vol. 68, No. 1, 15.07.1999, p. 83-86.

Research output: Contribution to journalArticle

Butani, Lavjay ; Palmer, Joann ; Baluarte, H. J. ; Polinsky, Martin S. / Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. In: Transplantation. 1999 ; Vol. 68, No. 1. pp. 83-86.
@article{c80b03c1b4524172b301c848b5962423,
title = "Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection",
abstract = "Background. Mycophenolate mofetil (MMF) has been shown to be superior to azathioprine in reducing the incidence of acute rejection in adult renal transplant recipients. Although MMF is also being widely used in pediatric transplant patients, data documenting its safety are limited. Methods. A retrospective review of the transplant records at St. Christopher's Hospital for Children was conducted to identify patients who had received MMF. Results. Twenty-four children were switched from azathioprine to MMF, 4.8±2.9 years after transplantation. After an additional 0.8±0.4 years, MMF had been discontinued in 13 patients (54{\%}) because of adverse effects (AE). The only variable that predicted the development of AE was a lower calculated creatinine clearance at the time of initiation of MMF. Conclusions. In pediatric renal transplant recipients with impaired renal function, the use of MMF at the recommended dose is associated with an unacceptably high incidence of AE; in such patients, the MMF dose may require modification for the level of renal function.",
author = "Lavjay Butani and Joann Palmer and Baluarte, {H. J.} and Polinsky, {Martin S.}",
year = "1999",
month = "7",
day = "15",
language = "English (US)",
volume = "68",
pages = "83--86",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection

AU - Butani, Lavjay

AU - Palmer, Joann

AU - Baluarte, H. J.

AU - Polinsky, Martin S.

PY - 1999/7/15

Y1 - 1999/7/15

N2 - Background. Mycophenolate mofetil (MMF) has been shown to be superior to azathioprine in reducing the incidence of acute rejection in adult renal transplant recipients. Although MMF is also being widely used in pediatric transplant patients, data documenting its safety are limited. Methods. A retrospective review of the transplant records at St. Christopher's Hospital for Children was conducted to identify patients who had received MMF. Results. Twenty-four children were switched from azathioprine to MMF, 4.8±2.9 years after transplantation. After an additional 0.8±0.4 years, MMF had been discontinued in 13 patients (54%) because of adverse effects (AE). The only variable that predicted the development of AE was a lower calculated creatinine clearance at the time of initiation of MMF. Conclusions. In pediatric renal transplant recipients with impaired renal function, the use of MMF at the recommended dose is associated with an unacceptably high incidence of AE; in such patients, the MMF dose may require modification for the level of renal function.

AB - Background. Mycophenolate mofetil (MMF) has been shown to be superior to azathioprine in reducing the incidence of acute rejection in adult renal transplant recipients. Although MMF is also being widely used in pediatric transplant patients, data documenting its safety are limited. Methods. A retrospective review of the transplant records at St. Christopher's Hospital for Children was conducted to identify patients who had received MMF. Results. Twenty-four children were switched from azathioprine to MMF, 4.8±2.9 years after transplantation. After an additional 0.8±0.4 years, MMF had been discontinued in 13 patients (54%) because of adverse effects (AE). The only variable that predicted the development of AE was a lower calculated creatinine clearance at the time of initiation of MMF. Conclusions. In pediatric renal transplant recipients with impaired renal function, the use of MMF at the recommended dose is associated with an unacceptably high incidence of AE; in such patients, the MMF dose may require modification for the level of renal function.

UR - http://www.scopus.com/inward/record.url?scp=0033565911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033565911&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 83

EP - 86

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -